Hybridan Small Cap Feast - 25 Jan 23

25 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Morning Note – 25 January 2023

hVIVO - Trading update – a strong H2 that market was waiting to see

hVIVO issued a positive trading update for FY 2022, citing revenues (including other income) of £50.6m, which was above its previous guidance of £50m and FC’s revenue forecast of £49.1m, EBITDA margins not less than 17% and period-end cash of £28.4m (FC £22.8m est). Whilst this performance was positively affected by the recognition of postponement and cancellations fees amounting to c.£1m, underlying EBITDA was c.£7.6m (9% above FC £7.0m est) implying margins were c.15%, towards the top end of i

LIBERUM: hVIVO plc* - Update exceeds expectations

Hybridan Small Cap Feast - 17 Jan 23

17 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Morning Note – 17 January 2023

hVIVO - Defensive growth in a challenging market (10 for 23 extract)

hVIVO is a UK-based specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The surge in demand for challenge studies (illustrated by repeat, as well as more complex, contracts with big pharma and biotech) is driven by the economic and clinical arguments of testing drugs/vaccines in a controlled environment as opposed to the larger, more expensive and, arguably, more unpred

This Week's AIM Highlights 6th January 2023

LIBERUM: hVIVO plc* - Positive start to 2023

LIBERUM: UK Small & Mid Cap Dispatches

Morning Note – 4 January 2023

Hybridan Small Cap Feast 19/12/22

Dish of the day Joiners: No joiners today Leavers: Joules (JOUL.L) has left AIM. What’s cooking in the IPO kitchen?** Celsius Resources intends to join AIM. Currently ASX listed, Celsius is a natural resources exploration and development company principally seeking to explore and develop potential world-class copper-gold assets in the Philippines and a cobalt asset in Namibia. Amount planning to raise and anticipated market cap TBC. Expected late December 2022. Conviction Life Sciences, a newly

Hybridan Small Cap Feast 10-11-2022

*A corporate client of Hybridan LLP ** Arranged by most recent first *** Alphabetically arranged Dish of the day Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** One Health Group plc, intends to join the AQSE Growth Market. The group provides medical services, in the form of elective surgical care, to support the NHS in the management of patients, through a growing network of community-based outreach clinics and independent hospitals. One H

LIBERUM: hVIVO plc* - Another contract win underpins forecasts

hVIVO - £13.6m RSV human challenge contract

hVIVO has signed a £13.6m contract with a US biotechnology client to test its antiviral product in a Phase IIa study, using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model. The study is expected to commence in Q3/Q4 2023, with revenues to be recognised in 2023 and 2024. Not only is this study the largest RSV study contracted to date for which hVIVO should have received a non-refundable upfront reservation fee of c.£2m, but it builds revenue visibility into FY 2023. Moreover

Top Picks for 2023 - 2022 review and outlook for 2023

On 10 January last year, we set out our ten top stock picks for 2022, in what turned out to be a very poor twelve months for global equities, due to war, accelerating inflation, political instability and recession fears. Between 7 January 2022 and 31 December 2022, the AIM All-Share Index declined 30.0%, whilst the average performance of our ten top picks was -24.7%, a modest relative outperformance. In this note we discuss the performance of our 2022 top picks, equities trends in 2022, and our

QuotedData’s Real Estate Monthly Roundup – January 2023

Performance - 2022 ended with another difficult month for property companies as the sector continues to get to grips with the impact of higher interest rates. There were several funds that performed well during December, however, with secondary shopping centre landlord Capital & Regional top of the pile. For a second month on the trot Home REIT saw its share price tank after it came under attack from a short seller in November. Valuation moves - It was a mixed bag for valuations, with six-month

SHORE CAPITAL - Sureserve Group+ (SUR, House Stock at 91p)

This Week's AIM Highlights 20th January 2023

Cenkos: Bidstack Group Plc -- Termination of Coverage

Cenkos Securities plc has terminated coverage on Bidstack Group Plc. Our previous recommendation (BUY) and forecasts can no longer be relied upon. Please contact Cenkos for further information.

SHORE CAPITAL - Sureserve Group ^ (SUR) - House Stock at 85p

City of London Investments (CLIG LN) - Six-month trading update

CLIG’s half-year pre close trading update reveals $9.15bn of Funds Under Management (FUM): up in 2Q, but down 1% since 30 June. CLIG’s run-rate profit remains at levels reported in the 1Q IMS; the interim DPS remains at 11p.

Morning Note – 20 January 2023

Feedback on CMD

Franchise Brands held a well-attended CMD yesterday which highlighted the group's strategy, the robust performance of its two key operating divisions (B2B and Filta International), and how the application of technology and effective marketing are driving growth.

Hybridan Small Cap Feast - 23 Jan 23

23 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Morning Note – 24 January 2023

Morning Note – 23 January 2023

WHI Support Services Sector Comment: Challenges and opportunities

Bleak expectations for the UK economy in 2023 anticipate underperformance against other G7 countries based on factors such as (a) the UK's higher than average mortgage rate sensitivity and (b) relative exposure to high gas and energy prices. Some measure of political / economic stability has returned, though this arguably remains a brittle quality, given the scope for dissent within the Conservative party and the unpredictable impacts of industrial action, among a range of factors. All of this s

Hybridan Small Cap Feast - 18 Jan 23

18 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object

Hybridan Small Cap Feast - 20 Jan 23

20 January 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object